Supernus Pharmaceuticals, Inc. (SUPN)
47.76
-1.08
(-2.21%)
USD |
NASDAQ |
Mar 20, 16:00
47.74
-0.02
(-0.03%)
After-Hours: 20:00
Supernus Pharmaceuticals Research and Development Expense (Quarterly) : 27.34M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 434.00M |
| BridgeBio Pharma, Inc. | 116.42M |
| Corcept Therapeutics, Inc. | 64.86M |
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| Cytokinetics, Inc. | 101.54M |